Drug Profile
Lobaplatin
Alternative Names: D 19466Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Zentaris
- Class Antineoplastics; Cyclobutanes; Platinum complexes; Small molecules
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Breast cancer; Chronic myeloid leukaemia; Small cell lung cancer
- Discontinued Cancer
Most Recent Events
- 13 May 2011 No development reported - Phase-II for Breast cancer in Canada (IV)
- 13 May 2011 No development reported - Phase-II for Chronic myeloid leukaemia in Canada (IV)
- 13 May 2011 No development reported - Phase-II for Small cell lung cancer in Canada (IV)